SCHEMBL4124782

SCHEMBL4124782

COC1(OC)CCCc2c(OS(=O)(=O)c3ccc(C)cc3)nc(N)nc21

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 2/20 0.46
KEAP1 Q14145 1/20 0.39
NFE2L2 Q16236 1/20 0.39
RORC P51449 1/20 0.37
KDM4E B2RXH2 1/20 0.34
POLB P06746 1/20 0.34
ALDH1A1 P00352 2/20 0.34
P2RY12 Q9H244 1/20 0.34
HSP90AA1 P07900 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
KMT2A Q03164 2/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
MEN1 O00255 1/20 0.31
CA12 O43570 1/20 0.31
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3341305 0.87 CYP2C19 (0.47) CYP2C19KEAP1NFE2L2RORCKDM4E
SCHEMBL4117844 0.83 CYP2C19 (0.47) CYP2C19KEAP1NFE2L2RORCKDM4E
SCHEMBL3812065 0.83 CYP2C19 (0.47) CYP2C19KEAP1NFE2L2RORCALDH1A1
SCHEMBL3820405 0.79 CYP2C19 (0.42) CYP2C19KEAP1NFE2L2RORCKDM4E
SCHEMBL4129860 0.78 CYP2C19 (0.61) CYP2C19KEAP1NFE2L2KDM4EALDH1A1
SCHEMBL4139046 0.77 CYP2C19 (0.41) CYP2C19KEAP1NFE2L2RORCALDH1A1
SCHEMBL4877590 0.72 CYP2C19 (0.51) CYP2C19KEAP1NFE2L2KDM4EPOLB
SCHEMBL2166315 0.71 ALDH1A1 (0.49) CYP2C19KEAP1NFE2L2KDM4EPOLB
SCHEMBL4878194 0.71 ALDH1A1 (0.47) CYP2C19KEAP1NFE2L2KDM4EPOLB
SCHEMBL3131985 0.70 CYP2C19 (0.47) CYP2C19KEAP1NFE2L2ALDH1A1P2RY12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436005-B2 Macrocyclic pyrimidine derivatives ABBOTT LABORATORIES (US) 2013-05-07 US disclosed
US-20090253678-A1 MACROCYCLIC PYRIMIDINE DERIVATIVES ABBOTT LABORATORIES (US) 2009-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253678-A1 MACROCYCLIC PYRIMIDINE DERIVATIVES DPYD, TYMS, TYMP CYP2C19 1402/4885KEAP1 827/4885NFE2L2 930/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.